Literature DB >> 34251555

Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.

Norifumi Iseda1, Shinji Itoh2, Tomoharu Yoshizumi1, Takahiro Tomiyama1, Akinari Morinaga1, Tomonari Shimagaki1, Huanlin Wang1, Takeshi Kurihara1, Takeo Toshima1, Yoshihiro Nagao1, Noboru Harada1, Yoshinao Oda3, Masaki Mori1.   

Abstract

BACKGROUND: Systemic inflammation has been correlated with worse survival for some cancers. We evaluated prognostic values of various inflammatory factor combinations in patients who underwent resections for hepatocellular carcinoma (HCC).
METHODS: We retrospectively analysed 306 consecutive patients with HCC who underwent curative liver resections. After assessing eight combinations of inflammatory markers for predictive value for recurrence, we focused on lymphocyte-to-C-reactive protein ratio (LCR) to elucidate its associations with recurrence-free survival (RFS) and overall survival (OS) in univariate and multivariate analyses (Cox proportional hazards model). We also used immunohistochemical CD34 and CD8 staining to investigate the mechanism of LCR elevation.
RESULTS: LCR showed the highest association with RFS in HCC patients among the compared indices. High preoperative LCR correlated with a high serum albumin concentration, small tumour size, early Barcelona Clinic Liver Cancer stage and low rates of microscopic vascular invasion and microscopic intrahepatic metastasis. Higher preoperative LCR was an independent predictor of longer RFS and OS in this cohort. High LCR patients had fewer vessels encapsulating tumour clusters, and higher intratumoural CD8+ T-cell counts than low LCR patients.
CONCLUSIONS: Preoperative LCR is a novel and convenient prognostic marker for patients with HCC, and is associated with the tumour microenvironment immune status.
© 2021. Japan Society of Clinical Oncology.

Entities:  

Keywords:  Hepatocellular carcinoma; Immune status; Lymphocyte-to-C-reactive protein ratio; Systemic inflammation; Vessels encapsulating the tumour cluster

Year:  2021        PMID: 34251555     DOI: 10.1007/s10147-021-01985-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  36 in total

1.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Luis F Porrata; Kay Ristow; Thomas M Habermann; Thomas E Witzig; Joseph P Colgan; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma.

Authors:  Richard A Smith; Lorraine Bosonnet; Michael Raraty; Robert Sutton; John P Neoptolemos; Fiona Campbell; Paula Ghaneh
Journal:  Am J Surg       Date:  2008-07-17       Impact factor: 2.565

Review 4.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

5.  Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis.

Authors:  Shinji Itoh; Ken Shirabe; Akinobu Taketomi; Kazutoyo Morita; Norifumi Harimoto; Eiji Tsujita; Keishi Sugimachi; Yo-Ichi Yamashita; Tomonobu Gion; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-12-27       Impact factor: 2.549

6.  Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas.

Authors:  Shinji Itoh; Kazutoyo Morita; Shigeru Ueda; Keishi Sugimachi; Yo-ichi Yamashita; Tomonobu Gion; Kengo Fukuzawa; Kenzo Wakasugi; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2009-10-14       Impact factor: 5.344

Review 7.  Cancer-related inflammation and treatment effectiveness.

Authors:  Connie I Diakos; Kellie A Charles; Donald C McMillan; Stephen J Clarke
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

8.  A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI).

Authors:  D J Pinato; B V North; R Sharma
Journal:  Br J Cancer       Date:  2012-03-20       Impact factor: 7.640

9.  C-reactive protein/albumin ratio predicts 90-day mortality of septic patients.

Authors:  Otavio T Ranzani; Fernando Godinho Zampieri; Daniel Neves Forte; Luciano Cesar Pontes Azevedo; Marcelo Park
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

10.  Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.

Authors:  M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

View more
  3 in total

1.  Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.

Authors:  He-Yang Zhang; Hai-Lun Xie; Guo-Tian Ruan; Qi Zhang; Yi-Zhong Ge; Xiao-Yue Liu; Meng Tang; Meng-Meng Song; Shi-Qi Lin; Ming Yang; Xiao-Wei Zhang; Hong-Xia Xu; Chun-Hua Song; Han-Ping Shi
Journal:  BMC Cancer       Date:  2022-10-20       Impact factor: 4.638

2.  Preoperative lymphocyte-to-C-reactive protein ratio predicts hepatocellular carcinoma recurrence after surgery.

Authors:  Masashi Utsumi; Masaru Inagaki; Koji Kitada; Naoyuki Tokunaga; Midori Kondo; Yuya Sakurai; Kosuke Yunoki; Ryosuke Hamano; Hideaki Miyasou; Yousuke Tsunemitsu; Shinya Otsuka
Journal:  Ann Surg Treat Res       Date:  2022-08-05       Impact factor: 1.766

3.  High-Risk Obesity Phenotypes: Target for Multimorbidity Prevention at the ROFEMI Study.

Authors:  Juana Carretero-Gómez; Pablo Pérez-Martínez; José Miguel Seguí-Ripoll; Francisco Javier Carrasco-Sánchez; Nagore Lois Martínez; Esther Fernández Pérez; Onán Pérez Hernández; Miguel Ángel García Ordoñez; Candelaria Martín González; Juan Francisco Vigueras-Pérez; Francesc Puchades; María Cristina Blasco Avaria; María Isabel Pérez Soto; Javier Ena; José Carlos Arévalo-Lorido
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.